Low-Dose Spironolactone and Cardiovascular Outcomes in Patients With Stage 3b Chronic Kidney Disease
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Nature Medicine
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Low-dose spironolactone and cardiovascular outcomes in moderate stage chronic kidney disease: a randomized controlled trial
Nat. Med. 2024 Sep 30;[EPub Ahead of Print], FDR Hobbs, RJ McManus, CJ Taylor, NR Jones, JK Rahman, J Wolstenholme, S Kim, J Kwon, L Jones, JA Hirst, LM Yu, S MortFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.